-
Stifel's ASCO Abstract Cheat Sheet
Thursday, May 18, 2017 - 9:57am | 587Read More...Commenting on the abstracts for the annual American Society of Clinical Oncology, or ASCO, meeting released after market close on Wednesday, Stifel gave its overview of the specific abstracts. The ASCO is scheduled to be held June 2–6 this year. Sell-Off In NewLink Genetics Unfounded...
-
Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators
Monday, June 13, 2016 - 9:37am | 597Read More...The new type of drug that uses the body's immune system to fight cancers has hit the bulls eye. But, Reuters has reported that a top U.S. regulator is concerned too many companies are focused on the same approach. This approach disables the PD-1 protein tumors use to dodge the immune system. '...
-
Goldman Confident In Merck's Keytruda
Tuesday, June 7, 2016 - 2:43pm | 288Read More...Goldman Sachs said evidence of Merck & Co., Inc. (NYSE: MRK)'s Keytruda benefit as a single agent continues to build as registrational monotherapy studies read out. Merck's data presented at ASCO (American Society of Clinical Oncology) include updates on new tumors, existing tumors and...
-
EXCLUSIVE With Ziopharm CEO: Here's Why Our Genetic Programming Is Different From Competitors
Friday, December 18, 2015 - 12:59pm | 557Read More...• ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) CEO Dr. Laurence Cooper believes that the company’s cell programming languages set it apart from other cancer researchers. • The company’s Sleeping Beauty platform allows for T cell modification without the use of a viral...
-
3 Stocks That Made A Big Impact At ASCO
Wednesday, June 3, 2015 - 11:55am | 599Read More...The American Society of Clinical Oncology (ASCO) conference is wrapping up in Chicago. The three day conference brings together thousands of oncology professionals and pharmaceutical companies to share research and new best practices. H.C. Wainwright analyst Reni Benjamin attended several...
-
UBS Reviews ASCO, Notes Weekend Data Points From 2 Companies
Monday, June 1, 2015 - 9:38am | 382Read More...In a report published Sunday, UBS analyst Marc Goodman reviewed key data points from the American Society of Clinical Oncology (ASCO). AbbVie: Ph-III Helios Data 'Quite Strong' Goodman noted that AbbVie Inc (NYSE: ABBV)'s data for Helios Imbruvica combo in 2L CLL/SLL was "...
-
Here's Why Oppenheimer Upgraded ImmunoGen To Outperform
Friday, February 6, 2015 - 11:45am | 175Read More...Christopher Marai of Oppenheimer on Thursday upgraded shares of ImmunoGen, Inc. (NASDAQ: IMGN) to Outperform from Perform with an $11 price target as recent weakness in shares following disappointing results from MARIANNE creates a buying opportunity given a "catalyst-rich" next 12 months. "We view...
-
ASCO Meeting Day 1: Preserving Fertility And Reducing Side Effects
Wednesday, June 4, 2014 - 10:11am | 420Read More...The 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) just wrapped up in Chicago, Illinois with meetings and presentations from May 30 to June 3. At this year's 50th Annual Meeting, more than 25,000 cancer specialists gathered to discuss research on the theme of "...
